Rich Daly

Biography

Upon the completion of the acquisition of Catalyst Pharmaceuticals by Angelini Pharma in July 2026, Rich was named President, Global Rare Disease Business Unit. From January 2024, Rich was the President and CEO of Catalyst Pharmaceuticals after being a member of the Board of Directors for 9 years. Having decades of experience in diabetes, GI, and oncology, Rich is drawn to the rare disease space due to the proximity of patients and their caregivers and the ability to use their insights to guide the business.

“Each of us is a patient in some measure. I’m humbled and grateful to have come through my own healthcare challenges, and it makes me want to work diligently every day to help patients who are waiting for life-changing treatments.”

Other Notable Roles:
President and CEO, Catalyst Pharmaceuticals
President, CARsgen Therapeutics Corporation
Chief Operating Officer, BeyondSpring Pharmaceuticals
Chairman and CEO, Neuralstem, Inc.
Partner, RavineRock Partners
President, AstraZeneca, US Diabetes

Board Participation:
Board of Directors, Catalyst Pharmaceuticals
Board of Directors, Opiant Pharmaceuticals – Member of Compensation and Audit Committees
Board of Directors, Synergy Pharmaceuticals – Chair, Nominations and Corporate Governance Committee, Member of Compensation Committee

Degrees:
Bachelor of Science, Microbiology, the University of Notre Dame
MBA, Kellogg School of Management, Northwestern University